Physician profile
Kasey Walker
NPI 1174384465
$775.22
in general payments reported to CMS, 2019-2025
14 companies · $743 in 2025
The $743 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $31.99 · 2025: $743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $775.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $149.97 | 2024-2025 | |
| Novo Nordisk INC | $130.20 | 2025 | Ozempic, Rybelsus |
| Solventum Corporation | $129.07 | 2025 | Prevena |
| Astellas Pharma US INC | $92.60 | 2025 | Veozah |
| Lundbeck LLC | $80.72 | 2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.64 | 2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $34.26 | 2025 | Breztri |
| Pfizer INC. | $21.20 | 2025 | |
| Xeris Pharmaceuticals, INC. | $19.51 | 2025 | Keveyis |
| Merck Sharp & Dohme LLC | $17.97 | 2025 | Capvaxive, Gardasil 9 |
| Glaxosmithkline, LLC. | $17.37 | 2025 | Trelegy Ellipta |
| Amgen INC. | $16.91 | 2025 | Otezla, Repatha |
| Verity Pharmaceuticals INC. | $15.74 | 2025 | Tlando |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.06 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kasey Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.